AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02307422 — intervention group
Intervention type: GENETIC
Intervention: IL-1 Genotypes, other SNPs associated with CAD
Description: Genotyping will be carried out by a CLIA-certified genotyping facility at ILI, Waltham MA. DNA concentrations will be adjusted to a range compatible with multiple PCR conditions. Genotyping will be accomplished by performing multiplex polymerase chain reactions (PCR) specifically targeting the surrounding sequences for the SNPs being studied. A single base extension assay will be hybridized to a 48-plex microarray plate and read on a SNPstream Genotyping System (Beckman-Coulter).
Study NCT02801747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart2 (HTH2)
Description: The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.
Study NCT01191125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical food with AN777
Description: Two(220 mL)servings every day for six months
Study NCT01191125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral nutritional formula
Description: Two (220 mL) servings daily for six months
Study NCT02875132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab at 200mg IV infusion every 3 weeks
Study NCT02539433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: F-18-F-DOPA
Description: F-18-F-DOPA i.v. injection of a dose of up to 8.5 mCi. PET scanning started 60-90 minutes post injection
Study NCT03598270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous. Day 1
Study NCT03598270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m². Intravenous. Day 1
Study NCT03598270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m². Intravenous. Day 1
Study NCT03598270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niraparib
Description: 200 mg or 300 mg. Oral. From day 1 to 21
Study NCT03598270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 200 mg or 300 mg. Oral. From day 1 to 21
Study NCT03598270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m². Intravenous. Day 1 and day 8.
Study NCT03598270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m². Intravenous. Day 1 and day 8.
Study NCT03598270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: 30 mg/m². Intravenous. Day 1
Study NCT03598270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: 30 mg/m². Intravenous. Day 1
Study NCT03598270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg. Intravenous. Day 1
Study NCT02938598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Depression Education and Care-Seeking Motivation
Description: Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation
Study NCT01041638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study NCT01041638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01041638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV
Study NCT01041638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO
Study NCT01041638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given IV or SC
Study NCT00349453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone (L1)
Description: 50-100 mg/kg body weight daily
Study NCT00349453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone (L1)
Description: 75 mg/kg body weight daily
Study NCT00349453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desferrioxamine
Description: 35-50 mg/kg body weight on 2 or more days per week
Study NCT01417741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture Needle
Description: A small 1.8 mm needle to be placed in the P6 acupuncture point on the wrist
Study NCT01037179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
Study NCT02930733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 30 ml %0,25 bupivacaine bilaterally
Study NCT02930733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 ml saline subcutaneously bilaterally
Study NCT01513668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Extended release Gel tabs 650 mg
Study NCT01513668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Extended release Gel tabs 650 mg
Study NCT02631109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2000U/m2 day5
Study NCT02631109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 25mg/m2 day1
Study NCT03250858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised advice
Description: Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
Study NCT03250858 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-personalised advice
Description: Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalized dietary advice for improved food choice based on standard population health guidelines.
Study NCT04563910 — intervention group
Intervention type: OTHER
Intervention: young mania rating scale
Description: questionnaires to the patients and their family after their written consent
Study NCT01395381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo given once
Study NCT01395381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: single dose albendazole given at the time of enrollment
Study NCT00694603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given intravenously once per week.
Study NCT02631109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100 mg/m2 was administered once on the first day of every week
Study NCT02631109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
Study NCT03867383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Chloride
Description: All included in intervention description.~1 gram of calcium chloride in total 60 milliliters normal saline
Study NCT02191267 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F18]-T807
Description: \[F18\]-T807 PET Scan to measure tau deposition in the brain.
Study NCT02191267 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F18]-Florbetapir
Description: \[F18\]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
Study NCT02191267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI/MRS
Description: Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
Study NCT02191267 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Analysis for Genetic Risk Score for Tau.
Description: DNA will be extracted from previously acquired and de-identified frozen blood specimens using a standard protocol (Gentra Puregene Kit, Qiagen 158422). Genotyping will be performed using the iPLEX Sequenom MassARRAY platform and samples will be genotyped for single nucleotide polymorphisms (SNPs) associated with the deposition of neurofibrillary tangles.
Study NCT00599612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW856553
Description: A dose of 10mg GW856553 containing 50µCi of \[14C\]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.
Study NCT00955669 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptoms and Objective Examination
Description: 5.0\*108\~5.0\*109 MSCs and MNCs were transplant into impaired lower limbs by intramuscular injection
Study NCT00765674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 150 and 300 mg tablets
Study NCT00765674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 and 10 mg capsules
Study NCT00765674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: 12.5 and 25 mg capsules
Study NCT00765674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet
Study NCT00765674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: capsules
Study NCT00360438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: 0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.
Study NCT04606355 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: autostereoscopic, monocular dynamic force choice test
Study NCT04606355 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: stereopsis
Description: autostereoscopic dynamic forced-choice depth perception test
Study NCT04359940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: For clinical surveillance
Study NCT00606554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-assisted weaning program
Description: Closed-loop, knowledge-based, computer-assisted wean program initiated at the start of ventilator weaning.
Study NCT00606554 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care weaning
Description: Evidence-based standard of care weaning process.
Study NCT04406181 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HADS
Description: Hospital Anxiety and Depression Scale
Study NCT04606355 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Color vision
Description: autostereoscopic forced choice monocular or binocular color vision tests
Study NCT02002169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shower Technique Protocol
Description: Video and educational pamphlets of the STP will be used to assist in training participants randomized to this intervention. The participant must successfully demonstrate the STP on a training mannequin and be deemed by the study coordinator as ready to independently and correctly perform it before proceeding.
Study NCT02002169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard CVC Care
Description: Nuanced differences may be present at participating units; however, the key components of the intervention are 1) HD nurse delivery of CVC care 2) chlorhexidine or povidone cleansing 3) dry gauze dressing 4) standardized frequency. For both STP and control arms, participants whose HD centre uses polysporin triple ointment as part of standard CVC care will continue to have it applied as per program policy.
Study NCT02002169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard CVC Care
Description: Nuanced differences may be present at participating units; however, the key components of the intervention are 1) HD nurse delivery of CVC care 2) chlorhexidine or povidone cleansing 3) dry gauze dressing 4) standardized frequency. For both STP and control arms, participants whose HD centre uses polysporin triple ointment as part of standard CVC care will continue to have it applied as per program policy.
Study NCT02275104 — intervention group
Intervention type: DEVICE
Intervention: Contrast-enhanced ECG-gated multi-detector computed tomography
Description: Depending on potential contra-indications to iodine-enhanced computed tomography. It will be performed using the usual method on a 64-slice dual energy scanner. Data will be acquired after the injection of 120 mL iodine contrast media. Contrast will be injected at the rate of 4 mL/s without additional saline flush in order to obtain homogeneous enhancement of the 4 cardiac chambers, there by simplifying subsequent segmentation. The objective will be to obtain a 3-dimensional imaging of cardiac structures
Study NCT03867383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 milliliters normal saline
Study NCT02210884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Weekly oral supplementation with 15,000 IU vitamin D
Study NCT02210884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Weekly oral supplementation with 15,000 IU vitamin D
Study NCT00387712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Velocity based treadmill training
Description: 6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill speed is gradually progressed to meet the training heart rate goals for moderate aerobic exercise, when hemiparetic gait velocity can no longer be progressed, incline is added to achieve heart rate training goals. Progression is also based on participant's tolerance, abilities and safety.
Study NCT00387712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration based treadmill training
Description: 6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress. Progression is based on participant's tolerance, abilities and safety.
Study NCT02275104 — intervention group
Intervention type: DEVICE
Intervention: Magnetic resonance imaging
Description: Depending on potential contra-indications to gadolinium-enhanced magnetic resonance. It will be performed on the 1.5 Tesla clinical device associated to MUSIC equipment (Magnetom Avanto, Siemens, Erlangen, Germany). Myocardial fibrosis will be imaged using a free-breathing delayed-enhancement method initially developed for atrial imaging. The method uses a 3-dimensional, inversion recovery-prepared, ECG-gated and respiratory-navigated Turbo Fast Low Angle Shot sequence with fat saturation. Acquisition will be initiated 15 minutes after the injection of a double-dose of gadolinium-based contrast media.
Study NCT02275104 — intervention group
Intervention type: DEVICE
Intervention: Positron emission tomography
Description: Only in patients with a contra-indication to magnetic resonance imaging. It will be performed on a PET/CT 600 device. Acquisition will be preceded by a standard metabolic preparation for 18 fluoro-deoxy-glucose viability imaging. The objective will be to obtain a 3-dimensional imaging of ventricular scar.
Study NCT02275104 — intervention group
Intervention type: DEVICE
Intervention: Body surface mapping
Description: It will be obtained using a 252-electrode vest. The position of each electrode with respect to epicardium will be assessed at multi-detector computed tomography prior to mapping. In patients referred for ventricular arrhythmia, body surface mapping will aim at recording the clinical arrhythmia whenever possible. In patients referred for atrial arrhythmia, body surface mapping will aim at recording atrial fibrillation.
Study NCT02275104 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac ablation procedure
Description: Ventricular procedures will be performed endocardially using trans-septal or retro-aortic approach, potentially combined with sub-xiphoid epicardial access. Atrial procedures will be performed endocardially using trans-septal approach to access the left atrium. Bi-atrial bipolar contact mapping will be performed at high density during atrial fibrillation prior to ablation.
Study NCT01121068 — intervention group
Intervention type: OTHER
Intervention: Blood samplings
Description: About 3.5ml of blood will be drawn from the participants monthly.
Study NCT02763800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.
Study NCT02384681 — intervention group
Intervention type: OTHER
Intervention: Exposure to auditory fatigue
Description: 12-hour auditory exposure
Study NCT04083014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of a single dose anti-CD20 antibody and bortezomib
Description: Relapsed and refractory warm AIHA patients receive treatment of combination of a single dose anti-CD20 antibody and bortezomib twice during three months interval.
Study NCT03496454 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PfSPZ Challenge
Description: The administration of an injection PfSPZ Challenge in Gambian adults
Study NCT01626859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 3mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.
Study NCT01626859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 6mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks.
Study NCT01626859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 9mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.
Study NCT01653197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: No scratch off element
Study NCT02763800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo was administered in the form of oral tablets, given with 200 ml potable water
Study NCT04406181 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: a survey
Description: made up specifically for issues concerning the medical/psychological/access aspects during the COVID-19 outbreak
Study NCT02607774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam administered to all patients Days -7, 1 and 35.
Study NCT02607774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: secukinumab administered at Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24
Study NCT02976558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clown theatrical Performance
Study NCT02976558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture according to Traditional Chinese Medicine
Study NCT02976558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy TaKeTiNa
Study NCT00887315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and cisplatin
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV repeated every 21 days for 2 additional cycles. For patients randomized to group 1, the chemotherapy is identical to that administered for the first 2 cycles
Study NCT00887315 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and cisplatin Plus Hypofractionated Radiotherapy
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV for 2 cycles along with hypofractionated radiotherapy to all known sites of disease
Study NCT03732482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide capsules
Description: Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
Study NCT03732482 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost
Study NCT04830371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuTCV (Vi-CRM Typhoid conjugate vaccine)
Description: Single dose, Intramuscular administration
Study NCT04830371 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typbar-TCV
Description: Single dose, Intramuscular administration
Study NCT01800929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N6
Description: Children with N5 will be upgraded to the N6 for a period of up to 2 months to evaluate.
Study NCT01800929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N6
Description: Children with N5 will be upgraded to the N6 for a period of up to 2 months to evaluate.
Study NCT02605343 — intervention group
Intervention type: OTHER
Intervention: NeuroIDgenetix Test Panel
Description: The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
Study NCT04028804 — intervention group
Intervention type: PROCEDURE
Intervention: FDG PET
Description: Each patient will receive a single intravenous injection of FDG (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FDG are being drawn up or radioactive decay has reduced the amount of available.